PharmaCyte Biotech Inc (PMCB)

[1234jklm]

low volume mean longs are holding and shorts lack volatility to trade

No one is selling so close to ind submission which most of us expect in September October.

Most of us know how big this can be with FDA approval.

Most of us believe in kw and the company and accept that bios take time but we see his process is good and backed up by the advice and support of some of the world's leading oncologists.

Previous tests suggest the value for tumorous cancers could be great; breast, ascites, pancreas and more.

Modified pancreatic cells encapsulated in ciab has already worked for six months on rats to cure diabetes.

Mellingen worked with a suppressed immune system in mice to cure diabetes.

Put the two together and everything points to them working.

It's all great news but it's slow news and new money will only come with new investors who will come attracted by news.

Which will most likely be our partnership which the ir says is in progress and will come after ind success.

So I guess it's just about patience while the ind is prepared and submitted and the new team is added and made ready for trials and funding and partnership are announced.

All on track and making haste patiently.

Just a bit boring sitting round waiting though

And hoping the cell banks aren't delayed or unable to be validated.

Patience isn't easy.

But it is going to be worth it.